Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 plus endocrine therapy vs placebo plus endocrine therapy in postmenopausal hormone receptor-positive advanced breast cancer
2007-006050-25Phase 2Terminated
- Sponsor
- Amgen
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing AMG 479 plus endocrine therapy with Placebo plus endocrine therapy (2 arms). Primary endpoints: Progression-free survival hazard ratio and Qualitative PFS estimates. Started Feb 2008; status: terminated.
02
Drugs
ganitumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-006050-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006050-25.